Connect with us

Hi, what are you looking for?


Holocene Advisors says Merck’s offer undervalues Acceleron

Stock Markets30 minutes ago (Oct 13, 2021 05:41PM ET)

(C) Reuters. The Merck logo is seen on a sign at the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/Files

(Reuters) -Investment management firm Holocene Advisors said it will not back Merck & Co’s offer to buy Acceleron Pharma (NASDAQ:XLRN) Inc for $180 per share, saying it significantly undervalues the drugmaker.

Avoro Capital, which owns 7% of Acceleron stock, had also shared that view on Merck’s $11.5 billion bid for the company.

“A transaction now, at this price, is not compelling … (the offer) does not compensate XLRN shareholders adequately, given Acceleron’s strong pipeline and attractive long-term business prospects,” Holocene said in a statement on Wednesday.

The deal would give Merck access to Acceleron’s rare disease drug candidate, sotatercept, which the company expects could bring in billions of dollars in sales.

Merck did not respond to requests for comment.

Acceleron, meanwhile, said on Wednesday it fully supported the offer and there had been no further negotiation after it was accepted.

“We are currently on track to achieve more than 50% shares being tendered as part of this tender period,” said Todd James, Acceleron senior vice president, corporate affairs and investor relations, on a call with Reuters, noting that just over half of outstanding shares need to be tendered for deals to close.

Merck began its tender offer to buy Acceleron shares on Tuesday.

Holocene owned 1.42% of Acceleron’s traded shares as of June 30, and is among the top 20 investors in the company, according to data from Refinitiv.

Holocene Advisors says Merck’s offer undervalues Acceleron

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.


Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione.


Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum.


Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora.

Disclaimer: it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial or health advice. Copyright © 2021 Buzz Clever. All Rights Reserved